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Audit of use of stiripentol in adults with Dravet syndrome
S. Balestrini1,2,3 | S. M. Sisodiya1,2
1  | INTRODUCTION
Dravet syndrome (DS) is a severe genetic epileptic encephalopathy 
with onset in infancy, often associated with drug- resistant epilepsy, 
developmental slowing, cognitive impairment, occurrence of status 
epilepticus and elevated risk of early mortality.1–3 In most cases, the 
cause is a mutation in the voltage- gated sodium channel type I al-
pha subunit gene, SCN1A.4 The main challenges include seizure con-
trol, prevention of status epilepticus and optimizing development of 
cognitive function, where possible. The adult phenotype has been 
described in a number of previous studies.2,5–8 Adjustment of treat-
ment may be associated with improved seizure control, cognition and 
quality of life, even into later adult life.2,6 Sodium channel blockers, for 
example, carbamazepine, oxcarbazepine and phenytoin, should usually 
be avoided as they can aggravate both seizures and interictal EEG.9 
Lamotrigine can also cause seizure exacerbation,10 although has been 
reported to be beneficial in some cases.11 Effective treatment strate-
gies include valproic acid, clobazam, topiramate, levetiracetam, fenflu-
ramine and bromides,12–14 or dietary therapies (ketogenic or modified 
Atkins diet).15 There are ongoing studies on the use of cannabidiol in 
children with DS.16 Stiripentol was licensed under the European Med-
icine Agency Orphan Drug scheme in 2001 and is the only treatment 
for which a randomized, placebo- controlled trial has been performed 
in children with DS,17 showing that significantly more children with DS 
on stiripentol adjunctive therapy were seizure- free, or experienced at 
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Objectives: There are very few data available in the literature on the use of 
stiripentol in adults with Dravet syndrome (DS). DS cases are increasingly recog-
nized in adulthood, and more children with DS now survive to adulthood. The aim 
of the study was to document the effectiveness and tolerability of stiripentol in 
adults with DS.
Material and methods: We conducted an observational clinical audit in the epilepsy 
service of the National Hospital for Neurology and Neurosurgery, London (UK).
Results: We included 13 adult subjects with DS (eight females, five males). The 
responder (defined as more than 50% reduction in all seizure types) rate was 3/13 
(23%) at 36 months. The following other outcomes were reported: seizure exac-
erbation (3/13, 23%), no change (3/13, 23%), less than 50% reduction in seizures 
(2/13, 15%), more than 50% reduction in generalized tonic- clonic seizures but no 
other seizure types (1/13, 8%), undefined response (1/13, 8%). The retention rate 
was 62% after 1 year and 31% after 5 years. Adverse effects were reported in 
7/13 (54%): the most frequent were anorexia, weight loss, unsteadiness and tired-
ness. Withdrawal due to adverse effects occurred in 3/13 (23%).
Conclusions: Compared with previous studies on children with DS, our results 
show a lower responder rate and a similar tolerability profile. Stiripentol can be 
effective with a good tolerability profile. Our audit is small, but supports the use 
of stiripentol in adults with DS when first- line treatments are ineffective or not 
tolerated, in keeping with published guidelines.
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least a 50% reduction in seizure frequency, compared with placebo. 
Very few data are available about the use of stiripentol in adults, with 
reports for fewer than fifteen DS cases older than 18 years,18–21 and 
twelve healthy adult volunteers.22 We conducted a clinical audit to 
document the effectiveness and tolerability of stiripentol in adults with 
DS.
2  | MATERIAL AND METHODS
This project was reviewed and registered as an observational clini-
cal audit at the National Hospital for Neurology and Neurosurgery, 
London (UK). Ethics committee approval is not required for an 
audit, as clinical audit by definition does not involve intervention 
beyond usual clinical management.23
We included all adults (>18 years) with DS attending the epilepsy 
service with previous or current treatment with stiripentol, from Jan-
uary 2001 to July 2015. DS was defined according to the following 
clinical criteria: seizure onset in the first year of life, with prior normal 
psychomotor development, intractable epileptic seizures triggered by 
infections and increased temperature, with no evidence of structural- 
metabolic aetiology.1 Cases were identified by reviewing all known DS 
cases from clinical registers, reviewing all requests for SCN1A muta-
tion testing by the hospital clinical genetics service and local hospital 
pharmacy prescriptions of stiripentol. Demographic and clinical infor-
mation were gathered.
The following variables were included in the analysis: age, gen-
der, age at clinical diagnosis, age at genetic testing, SCN1A mutation 
details, seizure types, history of status epilepticus, antiepileptic drugs 
(AEDs) tried before the introduction of stiripentol, age at introduction 
of stiripentol, interval between genetic diagnosis and introduction of 
stiripentol, AEDs initially used with stiripentol, mean monthly seizure 
frequency before the introduction of stiripentol and while on stiripen-
tol treatment, maximum dose of stiripentol, adverse effects during 
treatment with stiripentol, and total duration of exposure to stiripen-
tol. Seizure exacerbation was defined as an increase of more than 
25% in seizure frequency compared with seizure frequency before the 
introduction of stiripentol.
Statistical analysis was performed using Stata/IC V.11.1 (Stata, 
TX, USA). Descriptive statistics (mean, minimum, maximum, standard 
deviation, and median—when appropriate) were used.
3  | RESULTS
We identified 32 adult cases with DS in our service. Thirteen adults 
with DS and previous or current treatment with stiripentol were 
identified and comprised eight females and five males. DS was diag-
nosed on the basis of clinical findings, at a mean age of 24 (SD 11, 
range 2–41). Genetic analysis was undertaken at a mean age of 27 
(SD 9, range 12–43). SCN1A mutation or rearrangements were found 
in 12 of the 13 patients included. All cases had multiple seizure 
types. Eight patients (62%) had a history of status epilepticus prior 
to the introduction of stiripentol. In five cases (29%), stiripentol was 
introduced in adolescence and continued into adulthood. The mean 
age at introduction of stiripentol was 26 years (SD 12, range 12–47). 
In four subjects, it was introduced seven to ten years (median 7.5) 
before the genetic analysis. In the other nine cases, it was introduced 
a few months to 6 years (median 1 year), after positive genetic 
testing for SCN1A mutation. At the time of stiripentol introduction, 
the mean number of AEDs already tried was 9 (range 3–15), and it 
was used with one to four concurrent AEDs. None of the cases was 
ever on monotherapy with stiripentol. Details of SCN1A mutations, 
seizure types, AED history and age at introduction of stiripentol are 
shown in Table 1.
3.1 | Effectiveness
The frequency of seizures (of any type) at the time of stiripentol 
introduction varied from daily to weekly. The daily dose varied 
from 250 mg to 3000 mg with a mean maximum daily dose of 
1604 mg. Over an average time of exposure to stiripentol of 
42 months (range 3–139), more than 50% reduction in frequency 
of all seizure types was reported in three cases (23%). The other 
outcomes were: less than 50% reduction in frequency of all 
seizure types in two cases (15%), no change in seizure frequency 
in three cases (23%), more than 50% reduction in frequency of 
generalized tonic- clonic seizures (GTCs) but no change in fre-
quency of other seizure types in one case (8%), seizure exac-
erbation in three cases (23%) and undefined response in one 
case (8%). One case had initially more than 50% reduction in 
frequency of GTCs, from weekly to monthly GTCs with a 45 day 
period without any GTCs, and became then free of GTCs for 
about 12 months, followed by GTCs recurrence precipitated by 
intense physical exercise. Before introduction of stiripentol, eight 
patients (62%) had had from one to multiple episodes of status 
epilepticus. Of these cases, four had no further episodes of 
status after the introduction of stiripentol until the latest follow-
 up, over an average time of 43 months (range 3–139) on 
stiripentol.
Withdrawal due to lack of efficacy occurred in four cases (31%). 
In seven cases (54%), treatment was still ongoing at the time of the 
audit (July 2015), after they had been on stiripentol for an aver-
age time of 62 months (range 10–139). The following medication 
changes were undertaken in these seven cases during the course 
of treatment with stiripentol: in two clobazam was introduced; in 
one carbamazepine was withdrawn and clobazam introduced; in 
one phenytoin was withdrawn; in one sodium valproate was intro-
duced; in one topiramate was withdrawn, sodium valproate, leveti-
racetam, zonisamide and perampanel were introduced sequentially 
(zonisamide was soon withdrawn due to lack of effectiveness) and a 
vagus nerve stimulator was recently inserted; one did not have any 
changes to concurrent AEDs. Five cases (39%) were on clobazam 
and 10 cases (77%) were on sodium valproate, as concurrent treat-
ment when stiripentol was initiated. In three cases, (23%) clobazam 
and in one case (8%) sodium valproate were introduced later on 
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during the course of treatment with stiripentol. Overall, at some 
point eight cases (62%) had concurrent treatment with clobazam 
and 11 cases (85%) with sodium valproate. A summary of stiripen-
tol effectiveness in the audited cohort is reported in Table 2.
3.2 | Tolerability
Adverse effects were not systemically sought as this was not a 
prospective study, but were reported in seven cases (54%). These 
were: anorexia (n=4), weight loss (n=4), unsteadiness (n=3), tired-
ness/somnolence (n=2), nausea (n=1), abdominal pain (n=1), diar-
rhoea (n=1), myelodysplasia (thrombocytopenia and neutropenia) 
(n=1), behavioural disturbance (n=1), increased tremor (n=1). In six 
cases, reduction or withdrawal of one or two concurrent AEDs 
was reported. Withdrawal of stiripentol due to adverse effects 
occurred in three cases (23%): one due to anorexia and weight 
loss together with lack of efficacy, one due to behavioural dis-
turbance and diarrhoea and one due to anorexia, unsteadiness 
TABLE  1 Details of SCN1A mutations, seizure types, AED history, and age at introduction of stiripentol
Case ID SCN1A mutations Type of mutations Seizure typesa
AEDs tried before the introduction of 
stiripentolb
Age at introduction 
of stiripentol (years)
1 c.4568T>C Missense Atonic, GTC, 
myoclonic
Carbamazepine, clonazepam, 
ethosuximide, lamotrigine, leveti-
racetam, nitrazepam, phenobarbi-
tone, phenytoin, piracetam, 
primidone, topiramate, vigabatrin
41
2 c.80G > C; c.3749C > T; 
c.3706- 2A > G
Missense, 
missense, 
splice- site
Focal, GTC, tonic Carbamazepine, clonazepam, 
gabapentin, lamotrigine, leveti-
racetam, phenobarbitone, phenytoin, 
sodium valproate
15
3 c.2792G>A Missense Focal, GTC Clobazam, lacosamide, lamotrigine, 
levetiracetam, pregabalin, topira-
mate, zonisamide
44
4 c.4369_4372dupCTGT Premature STOP 
codon
Focal, GTC, 
myoclonic
Carbamazepine, clobazam, ethosux-
imide, oxcarbazepine, piracetam
29
5 c.603- 2A>G Splice- site Focal, sGCT Carbamazepine, ethosuximide, 
lamotrigine, levetiracetam, 
phenobarbitone, phenytoin, 
pregabalin, topiramate, vigabatrin
25
6 c.429delGT Premature STOP 
codon
Focal, GTC, 
myoclonic
Carbamazepine, clonazepam, 
ethosuximide, lamotrigine, piracetam
14
7 c.2244G>A Premature STOP 
codon
Focal, GTC, 
myoclonic
Acetazolamide, carbamazepine, 
clobazam, clonazepam, diazepam, 
ethosuximide, lamotrigine, leveti-
racetam topiramate, vigabatrin
16
8 c.4913T>C Missense Focal, GTC, 
myoclonic
Carbamazepine, gabapentin, 
oxcarbazepine, phenytoin, sodium 
valproate, topiramate, vigabatrin
23
9 c.5639G>A Missense Atypical absences, 
focal, myoclonic
Primidone, topiramate 47
10 c.2837G>A Missense GTC, myoclonic Clobazam, lamotrigine, levetiracetam, 
phenytoin
28
11 c.2293G>A Missense Atypical absences, 
focal, GTC
Acetazolamide, carbamazepine, 
clonazepam, lamotrigine, nitrazepam, 
topiramate, vigabatrin, zonisamide
30
12 Not detected – Absences, atonic, 
clonic, focal, GTC, 
myoclonic, tonic
Carbamazepine, gabapentin, 
lamotrigine, phenytoin, vigabatrin
12
13 c.5359G>A Missense Atonic, clonic, focal, 
GTC, hemi- clonic, 
myoclonic, tonic
Carbamazepine, clobazam, clonaz-
epam, gabapentin, lamotrigine, 
phenobarbitone, phenytoin, 
topiramate
12
AED, antiepileptic drugs; GTC, generalized tonic clonic seizures; sGTC, generalized tonic clonic seizure with apparent focal onset.
aSeizure types were clinically determined.
bAEDs are not listed in the temporal order of introduction.
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and increased tremor. A summary of stiripentol tolerability in the 
audited cohort is reported in Table 2.
4  | DISCUSSION
In a small cohort, we show that stiripentol can be effective in 
adults with DS, with a reasonable tolerability profile. The responder 
rate in our cohort was lower than that from studies in children 
with DS. Not enough data on adult DS cases treated with stirip-
entol are available to make adequate comparisons with our findings. 
We note that some adults have no useful response to 
stiripentol.
A randomised placebo- controlled trial conducted in children with 
DS17 showed 15 of 21 (71%) were responders (seizure- free or expe-
rienced at least a 50% reduction in seizure frequency) on stiripentol, 
whereas there was only one responder of 20 (5%) on placebo (none 
were seizure- free). The frequency of responders was greater on 
stiripentol (95% Confidence Interval 52.1–90.7) than on placebo (95% 
Confidence Interval 0–14.6; P<.001). Significantly more DS cases 
on stiripentol adjunctive therapy experienced drug- related adverse 
events compared with patients who only had placebo add- on (100% 
vs 25%; P=.0009). The adverse events most frequently observed on 
stiripentol were drowsiness and loss of appetite, sometimes caus-
ing loss of weight. The mean age of the DS cases on stiripentol was 
9.4 years (interquartile range 3–16.7).
Inoue et al.18 performed a retrospective survey in Japan exam-
ining the effect of AEDs on clonic seizures or GTCs in DS and then 
started compassionate use of stiripentol as add- on therapy in an 
open- label multicenter study. They included 25 DS cases, with an 
older subgroup with age from 8 to 22 years (n=8). The study period 
lasted 6–34 months (mean 14.1). A specified protocol was used, with 
2–4- week periods of evaluation (early and late), which were compared 
with a 4- week baseline period. In the older subgroup, four of eight 
cases (50%) had more than 50% reduction of GTCs, including one 
who became seizure- free, in the early period, and five cases (63%) 
had more than 50% reduction of GTCs in the late period. Duration of 
seizures was shortened in four cases (50%) in the early period and in 
two cases (25%) in late period. The frequency of episodes of status 
epilepticus decreased in one of the eight older cases (13%). Stiripen-
tol was discontinued in two cases (after 89 months) because seizure 
frequency was unchanged. The adverse effects most often observed 
were loss of appetite, sleep disturbance, hyperactivity or irritability, 
and ataxia during the early and intermediate periods. In most cases, 
these effects disappeared after dose modification of other AEDs/
stiripentol, or in the late period.
A further prospective, open- label, multicentre study was con-
ducted in Japan,19 including 24 DS cases, already on treatment with 
clobazam and sodium valproate at stable doses for at least 4 weeks 
(bromide was also allowed as concomitant therapy). This cohort 
included an older subgroup aged 21–24 years (mean 23; n=4). The 
study consisted of a 4- week baseline, 4- week dose adjustment and 
12- week fixed- dose phase. Three of the four older subjects (75%) 
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had more than 50% reduction in frequency of clonic seizures or GTCs 
during the last 4 weeks of the fixed- dose phase vs baseline, including 
one who became seizure- free. After the 12- week fixed- dose phase, 
21 of the initial 24 DS cases entered the 40- week long- term admin-
istration phase.21 None of the older cases remained responders in 
the long- term (one terminated the study due to poor response with-
out entering the long- term phase). Adverse events were reported in 
all patients enrolled; the most frequent included somnolence, loss 
of appetite and ataxia, occurring mostly during the dose- adjustment 
phase and were of mild- to-moderate severity.
Strzelczyk et al.20 retrospectively evaluated health- care utilization 
over a 2- year period in patients with DS at an outpatient clinic of a 
German epilepsy centre. Thirteen DS cases were included. Of these, 
nine (mean age 10.3, range 3–23) were switched to adjunctive treat-
ment with stiripentol and clobazam and experienced more than 25% 
reduction in seizure frequency between baseline and follow- up phases 
of 1 year each.
One double- blind placebo- controlled dose ranging study, assess-
ing stiripentol pharmacokinetics, enrolled exclusively adult subjects 
(22–37 years, mean 29), but these were healthy volunteers.22 This 
study confirmed the Michaelis- Menten pharmacokinetic profile of 
stiripentol that was previously described in adult healthy volunteers 
and people with epilepsy.24,25 Only two adverse effects (one rhinitis 
and one pharyngitis) were observed, unlikely related to the treatment.
Recently, stiripentol was reported to be effective in treating 
super- refractory status epilepticus, on the basis of clinical and exper-
imental data.26,27 Three of five adult patients who were treated with 
stiripentol for super- refractory status epilepticus had resolution of 
status within 2–4 days after the start of stiripentol.26 A rodent model 
of established status epilepticus showed effectiveness of stiripentol 
when seizures had already become resistant to treatment with ben-
zodiazepines, by potentiating GABAergic inhibition. The action of 
stiripentol seemed independent of the benzodiazepine binding site on 
the GABAA receptor.27–30
The tolerability profile in our audited cohort was comparable with 
existing data, with anorexia, weight loss, unsteadiness and tiredness 
as the most common adverse effects. One case had severe haema-
tological adverse effects with myelodysplasia (thrombocytopenia and 
neutropenia). However, the response to stiripentol was so dramatic 
(with about 12 months free of GTCs compared with GTCs occurring 
on a weekly basis before the introduction of stiripentol), that parents 
and clinicians agreed to continue the treatment, with dose adjust-
ments and regular haematological monitoring. Lack of dose adjust-
ments of some other concurrent AEDs at the time of the introduction 
of stiripentol might have affected tolerability in general, but data on 
concurrent AED changes were not available for all cases.
Insufficient data were available to establish a relationship with the 
dose of stiripentol. Due to the retrospective design of the study and the 
small size of the cohort, effectiveness was assessed on all seizure types 
and GTCs, but not on the other single seizure types. In terms of effec-
tiveness, the responder rate (defined as more than 50% reduction in all 
seizure types) was 23% (3/13). More than 50% reduction in GTCs was 
observed in four cases (31%). It is important to note that all the reported 
cases had been exposed to sodium channel blockers, known to aggra-
vate seizures and potentially precipitate status epilepticus in DS.2,6,9 
This is likely related to the fact that ours was an adult cohort, with often 
late clinical (range 2–41 years) and genetic (range 12–43 years) diagno-
ses. At the time of the introduction of stiripentol, four cases were still 
on sodium channel blockers (i.e., oxcarbazepine, carbamazepine, lam-
otrigine and phenytoin). In two of these, oxcarbazepine or carbamaze-
pine was withdrawn at the same time as stiripentol was introduced (#4 
and #8). In case #3 carbamazepine was withdrawn after 5 months and 
in case #11 phenytoin was withdrawn 8 months after the introduction 
of stiripentol. Furthermore, some cases had reduction or withdrawal of 
other concurrent AEDs (i.e. sodium valproate, zonisamide, clobazam, 
topiramate) with the introduction of stiripentol (Table 2). All these con-
comitant AED changes might confound assessment of stiripentol effec-
tiveness. Furthermore, eight cases (62%) had concurrent treatment 
with clobazam and 11 cases (85%) with sodium valproate. Stiripentol 
has an inhibitory effect on clobazam metabolism, mostly mediated by 
CYP3A4 and CYP2C19, leading to increased plasma concentrations 
of both clobazam and its active metabolite, norclobazam (desmeth-
ylclobazam).17,31,32 This pharmacokinetic drug interaction, along with 
the fact that stiripentol and clobazam/norclobazam act through sep-
arate sites on the GABAA receptor,27–30 may contribute to the effec-
tiveness as well as the adverse effects of stiripentol. Conversely, data 
collected in two independent multicentre randomized, double- blind, 
placebo- controlled trials in DS patients, STICLO- France and STICLO- 
Italy,17,32 did not show any significant interaction between stiripentol 
and sodium valproate. Age may be another confounding factor in the 
assessment of the effectiveness of stiripentol. The DS adult phenotype 
tends to differ from the childhood pattern. Episodes of status epilep-
ticus become rarer, atypical absences and myoclonic seizures tend to 
decrease, whereas focal dyscognitive seizures persist.21
We report seizure exacerbation in three cases (23%). The reason 
for this is unknown, and this outcome is not described in the stiripen-
tol literature for adult cases and it is rarely reported in children with 
DS.17–21
Dravet syndrome cases are increasingly recognized in adulthood, 
and many children with DS survive to adulthood. Better treatment 
strategies are required. Stiripentol is an allosteric modulator of the 
GABAA receptor,29 proven to be effective and well- tolerated in chil-
dren with DS.21,33 There are no data available in the literature on treat-
ment with stiripentol of DS cases older than 24 years. Although this 
was a small retrospective study with incomplete information for some 
cases, it is the largest and oldest sample of DS adult cases treated 
with stiripentol and with the longest follow- up to our knowledge. In 
some cases, because there were other drug changes made on clinical 
grounds, we cannot be certain that the entire response observed after 
stiripentol introduction was due solely to stiripentol: this was an audit, 
not a prospective clinical trial.
In view of our findings, the effectiveness demonstrated in pre-
vious studies17,21 and its reasonable tolerability profile, we suggest 
stiripentol is worth considering for adults with DS and drug- resistant 
epilepsy when first- line treatments are ineffective or not tolerated, 
in keeping with recommendations from National Institute for Health 
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and Care Excellence guidelines in the UK.34 Stiripentol use may lead 
to improved seizure control, with reduction of hospitalization costs 
and subsequent better health- care service utilization, as previously 
shown.20 Prospective studies, including well- designed trials in larger 
cohorts, would seem warranted.
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